Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-oxo-2-phenylmethanesulfonyl-octahydro-pyrrolo[1,2-a]pyrazine-6-carboxylic acid [1-(n-hydroxycarbamimidoyl)-piperidin-4-ylmethyl]-amide
- Development stage
- Unknown
- Lead developer
- Biochem Pharmaceutical Industries
- Modality
- Small Molecules
01
Overview
This compound is a synthetic small molecule dipeptide derivative with the molecular formula C22H32N6O5S and a molecular weight of approximately 492.6 g/mol. It is not approved for clinical use and is classified as an experimental agent in chemical databases. The structure features a pyrrolopyrazine core with sulfonamide and amidino substituents. According to available biochemical data, it acts as an inhibitor of thrombin (prothrombin), suggesting potential anticoagulant or antithrombotic activity; however, there are no known clinical indications or trials for this compound in humans[3][5][6].
- Other names
- (6S,8aS)-N-((1-((E)-N'-hydroxycarbamimidoyl)piperidin-4-yl)methyl)-4-oxo-2-phenylmethanesulfonyl-octahydropyrrolo(1,2-a)piperazine-6-carboxamide(6S,8aS)-N-{1-[E-N'-hydroxycarbamimidoyl]piperidin-4-yl}methyl)-4-oxo-2-phenyImethanesulfonyl-octahydropyrrolo[1,2-a]piperazine–6-carboxamide
02
Targets
F2 (Thrombin)
Beyond the preview
Go deeper on 4-oxo-2-phenylmethanesulfonyl-octahydro-pyrrolo[1,2-a]pyrazine-6-carboxylic acid [1-(n-hydroxycarbamimidoyl)-piperidin-4-ylmethyl]-amide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4-oxo-2-phenylmethanesulfonyl-octahydro-pyrrolo[1,2-a]pyrazine-6-carboxylic acid [1-(n-hydroxycarbamimidoyl)-piperidin-4-ylmethyl]-amide.